Preclinical study of the DNA repair inhibitor Dbait in combination with chemotherapy in colorectal cancer

Journal of Gastroenterology

Volumn 47, Issue 3, 2012, Pages 266-275

  Devun, Flavien ^a,b,c   Bousquet, Guilhem ^a,b,c,d,e   Biau, Julian ^a,f,g   Herbette, Aurélie ^a,h   Roulin, Christophe ^a,i   Berger, Frédérique ⁱ   Sun, Jian Sheng ^a   Robine, Sylvie ^a,c,d   Dutreix, Marie ^a,b,c,i  

^a INSTITUT CURIE   (France)

^b Centre National de la Recherche Scientifique   (France)

^c INSERM   (France)

^d CNRS   (France)

^e SAINT LOUIS HOSPITAL   (France)

^f CENTRE JEAN PERRIN   (France)

^g UNIVERSITÉ CLERMONT AUVERGNE   (France)

^h Parc Scientifique de Luminy   (France)

ⁱ MUSÉUM NATIONAL D'HISTOIRE NATURELLE   (France)

Author keywords

Chemotherapy; Colorectal cancer; Dbait; DNA repair inhibitor; Mouse models

Indexed keywords

CAMPTOTHECIN; DBAIT MOLECULE; DNA; FLUOROURACIL; IRINOTECAN; OLIGONUCLEOTIDE; UNCLASSIFIED DRUG;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ANTINEOPLASTIC ACTIVITY; ARTICLE; CANCER COMBINATION CHEMOTHERAPY; CANCER INHIBITION; CANCER SIZE; CELL STRAIN HCT116; CELL STRAIN HT29; COLORECTAL CANCER; CONTROLLED STUDY; DNA DAMAGE; DNA REPAIR; DRUG EFFICACY; DRUG POTENTIATION; DRUG SAFETY; GENE MUTATION; GENETIC ENGINEERING; GENETIC TRANSFECTION; HISTOPATHOLOGY; HUMAN; HUMAN CELL; IN VITRO STUDY; IN VIVO STUDY; MOUSE; NONHUMAN; ONCOGENE K RAS; OUTCOME ASSESSMENT; OVERALL SURVIVAL; PRIORITY JOURNAL; SURVIVAL TIME;

ADENOCARCINOMA; ANIMALS; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; CAMPTOTHECIN; CELL LINE, TUMOR; COLORECTAL NEOPLASMS; DNA DAMAGE; DNA REPAIR; FLUOROURACIL; GENETIC ENGINEERING; HUMANS; MICE; MICE, INBRED C57BL; MICE, INBRED DBA; PROTO-ONCOGENE PROTEINS; PROTO-ONCOGENE PROTEINS P21(RAS); RAS PROTEINS; TIME FACTORS;

EID: 84863098708     PISSN: 09441174     EISSN: 14355922     Source Type: Journal    
DOI: 10.1007/s00535-011-0483-x     Document Type: Article

References (52)

1. Pasetto LM, D'Andrea MR, Jirillo A, Rossi E, Monfardini S. Stable disease in advanced colorectal cancer: therapeutic implications. Anticancer Res. 2006;26:511-22. (Pubitemid 43210321)
2. Augestad KM, Lindsetmo RO, Stulberg J, Reynolds H, Senagore A, Champagne B, et al. International preoperative rectal cancer management: staging, neoadjuvant treatment, and impact of multidisciplinary teams. World J Surg. 2010;34:2689-700.
3. Tamburini E, Tassinari D, Papi M, Nicoletti S, Fantini M, Ravaioli A. Preoperative chemotherapy in locally advanced rectal cancer: systematic review of literature. Recenti Prog Med. 2008;99:134-40. (Pubitemid 351548231)
4. Ceelen W, Pattyn P, Boterberg T, Peeters M. Pre-operative combined modality therapy in the management of locally advanced rectal cancer. Eur J Surg Oncol. 2006;32:259-68.
5. Douillard JY, Cunningham D, Roth AD, Navarro M, James RD, Karasek P, et al. Irinotecan combined with fluorouracil compared with fluorouracil alone as first-line treatment for metastatic colorectal cancer: a multicentre randomised trial. Lancet. 2000;355:1041-7. (Pubitemid 30162806)
6. Goldberg RM, Sargent DJ, Morton RF, Fuchs CS, Ramanathan RK, Williamson SK, et al. A randomized controlled trial of fluorouracil plus leucovorin, irinotecan, and oxaliplatin combinations in patients with previously untreated metastatic colorectal cancer. J Clin Oncol. 2004;22:23-30. (Pubitemid 41095110)
7. Saltz LB, Clarke S, Diaz-Rubio E, Scheithauer W, Figer A, Wong R, et al. Bevacizumab in combination with oxaliplatin-based chemotherapy as first-line therapy in metastatic colorectal cancer: a randomized phase III study. J Clin Oncol. 2008;26:2013-9.
8. Pieterse AH, Stiggelbout AM, Baas-Thijssen MC, van de Velde CJ, Marijnen CA. Benefit from preoperative radiotherapy in rectal cancer treatment: disease-free patients' and oncologists' preferences. Br J Cancer. 2007;97:717-24. (Pubitemid 47396298)
9. Dutreix M, Cosset JM, Sun JS. Molecular therapy in support to radiotherapy. Mutat Res. 2010;704:182-9.
10. Allal AS, Kahne T, Reverdin AK, Lippert H, Schlegel W, Reymond MA. Radioresistance-related proteins in rectal cancer. Proteomics. 2004;4:2261-9. (Pubitemid 39025326)
11. Collis SJ, DeWeese TL, Jeggo PA, Parker AR. The life and death of DNA-PK. Oncogene. 2005;24:949-61. (Pubitemid 40313872)
12. Stiff T, O'Driscoll M, Rief N, Iwabuchi K, Lobrich M, Jeggo PA. ATM and DNA-PK function redundantly to phosphorylate H2AX after exposure to ionizing radiation. Cancer Res. 2004;64:2390-6. (Pubitemid 38523891)
13. Lobrich M, Shibata A, Beucher A, Fisher A, Ensminger M, Goodarzi AA, et al. GammaH2AX foci analysis for monitoring DNA double-strand break repair: strengths, limitations and optimization. Cell Cycle. 2010;9:662-9.
14. Quanz M, Berthault N, Roulin C, Roy M, Herbette A, Agrario C, et al. Small-molecule drugs mimicking DNA damage: a new strategy for sensitizing tumors to radiotherapy. Clin Cancer Res. 2009;15:1308-16.
15. Quanz M, Chassoux D, Berthault N, Agrario C, Sun JS, Dutreix M. Hyperactivation of DNA-PK by double-strand break mimicking molecules disorganizes DNA damage response. PLoS One. 2009;4:e6298.
16. Hsiang YH, Lihou MG, Liu LF. Arrest of replication forks by drug-stabilized topoisomerase I-DNA cleavable complexes as a mechanism of cell killing by camptothecin. Cancer Res. 1989;49:5077-82. (Pubitemid 19239347)
17. Swann PF, Waters TR, Moulton DC, Xu YZ, Zheng Q, Edwards M, et al. Role of postreplicative DNA mismatch repair in the cytotoxic action of thioguanine. Science. 1996;273:1109-11.
18. Janssen KP, Alberici P, Fsihi H, Gaspar C, Breukel C, Franken P, et al. APC and oncogenic KRAS are synergistic in enhancing Wnt signaling in intestinal tumor formation and progression. Gastroenterology. 2006;131:1096-109. (Pubitemid 44498698)
19. Fodde R, Edelmann W, Yang K, van Leeuwen C, Carlson C, Renault B, et al. A targeted chain-termination mutation in the mouse Apc gene results in multiple intestinal tumors. Proc Natl Acad Sci USA. 1994;91:8969-73.
20. Janssen KP, el-Marjou F, Pinto D, Sastre X, Rouillard D, Fouquet C, et al. Targeted expression of oncogenic K-ras in intestinal epithelium causes spontaneous tumorigenesis in mice. Gastroenterology. 2002;123:492-504. (Pubitemid 34827194)
21. Smits R, van Oordt W, Luz A, Zurcher C, Jagmohan-Changur S, Breukel C, et al. Apc1638N: a mouse model for familial adenomatous polyposis-associated desmoid tumors and cutaneous cysts. Gastroenterology. 1998;114:275-83. (Pubitemid 28093534)
22. Smith AJ, Stern HS, Penner M, Hay K, Mitri A, Bapat BV, et al. Somatic APC and K-ras codon 12 mutations in aberrant crypt foci from human colons. Cancer Res. 1994;54:5527-30. (Pubitemid 24346239)
23. Duez P, Dehon G, Kumps A, Dubois J. Statistics of the Comet assay: a key to discriminate between genotoxic effects. Mutagenesis. 2003;18:159-66. (Pubitemid 36336533)
24. Kunz C, Focke F, Saito Y, Schuermann D, Lettieri T, Selfridge J, et al. Base excision by thymine DNA glycosylase mediates DNA-directed cytotoxicity of 5-fluorouracil. PLoS Biol. 2009;7:e91.
25. Curtin NJ. PARP inhibitors for cancer therapy. Expert Rev Mol Med. 2005;7:1-20.
26. Di Paola R, Mazzon E, Xu W, Genovese T, Ferrraris D, Muia C, et al. Treatment with PARP-1 inhibitors, GPI 15427 or GPI 16539, ameliorates intestinal damage in rat models of colitis and shock. Eur J Pharmacol. 2005;527:163-71. (Pubitemid 41745164)
27. De Soto JA, Wang X, Tominaga Y, Wang RH, Cao L, Qiao W, et al. The inhibition and treatment of breast cancer with poly (ADP-ribose) polymerase (PARP-1) inhibitors. Int J Biol Sci. 2006;2:179-85. (Pubitemid 44031562)
28. Sarkaria JN. Identifying inhibitors of ATM and ATR kinase activities. Methods: Mol Med. 2003;85:49-56.
29. Shinohara ET, Geng L, Tan J, Chen H, Shir Y, Edwards E, et al. DNA-dependent protein kinase is a molecular target for the development of noncytotoxic radiation-sensitizing drugs. Cancer Res. 2005;65:4987-92. (Pubitemid 40827302)
30. He X, He L, Hannon GJ. The guardian's little helper: microRNAs in the p53 tumor suppressor network. Cancer Res. 2007;67:11099-101. (Pubitemid 350248530)
31. Li GC, He F, Shao X, Urano M, Shen L, Kim D, et al. Adenovirus-mediated heat-activated antisense Ku70 expression radiosensitizes tumor cells in vitro and in vivo. Cancer Res. 2003;63:3268-74. (Pubitemid 36735882)
32. Brueckner B, Kuck D, Lyko F. DNA methyltransferase inhibitors for cancer therapy. Cancer J. 2007;13:17-22.
33. Kashishian A, Douangpanya H, Clark D, Schlachter ST, Eary CT, Schiro JG, et al. DNA-dependent protein kinase inhibitors as drug candidates for the treatment of cancer. Mol Cancer Ther. 2003;2:1257-64.
34. Peng Y, Zhang Q, Nagasawa H, Okayasu R, Liber HL, Bedford JS. Silencing expression of the catalytic subunit of DNA-dependent protein kinase by small interfering RNA sensitizes human cells for radiation-induced chromosome damage, cell killing, and mutation. Cancer Res. 2002;62:6400-4. (Pubitemid 35364094)
35. Collis SJ, Swartz MJ, Nelson WG, DeWeese TL. Enhanced radiation and chemotherapy-mediated cell killing of human cancer cells by small inhibitory RNA silencing of DNA repair factors. Cancer Res. 2003;63:1550-4. (Pubitemid 36373642)
36. Bentle MS, Reinicke KE, Dong Y, Bey EA, Boothman DA. Nonhomologous end joining is essential for cellular resistance to the novel antitumor agent, beta-lapachone. Cancer Res. 2007;67:6936-45. (Pubitemid 47105541)
37. Powell SM, Zilz N, Beazer-Barclay Y, Bryan TM, Hamilton SR, Thibodeau SN, et al. APC mutations occur early during colorectal tumorigenesis. Nature. 1992;359:235-7.
38. Woo T, Okudela K, Yazawa T, Wada N, Ogawa N, Ishiwa N, et al. Prognostic value of KRAS mutations and Ki-67 expression in stage I lung adenocarcinomas. Lung Cancer. 2009;65:355-62.
39. Lievre A, Bachet JB, Le Corre D, Boige V, Landi B, Emile JF, et al. KRAS mutation status is predictive of response to cetuximab therapy in colorectal cancer. Cancer Res. 2006;66:3992-5.
40. Bernhard EJ, Stanbridge EJ, Gupta S, Gupta AK, Soto D, Bakanauskas VJ, et al. Direct evidence for the contribution of activated N-ras and K-ras oncogenes to increased intrinsic radiation resistance in human tumor cell lines. Cancer Res. 2000;60:6597-600.
41. Toulany M, Dittmann K, Baumann M, Rodemann HP. Radiosensitization of Ras-mutated human tumor cells in vitro by the specific EGF receptor antagonist BIBX1382BS. Radiother Oncol. 2005;74:117-29. (Pubitemid 40331868)
42. Mukherjee B, McEllin B, Camacho CV, Tomimatsu N, Sirasanagandala S, Nannepaga S, et al. EGFRvIII and DNA doublestrand break repair: a molecular mechanism for radioresistance in glioblastoma. Cancer Res. 2009;69:4252-9.
43. Tsunoda T, Takashima Y, Fujimoto T, Koyanagi M, Yoshida Y, Doi K, et al. Three-dimensionally specific inhibition of DNA repair-related genes by activated KRAS in colon crypt model. Neoplasia. 2010;12:397-404.
44. Arias-Lopez C, Lazaro-Trueba I, Kerr P, Lord CJ, Dexter T, Iravani M, et al. p53 modulates homologous recombination by transcriptional regulation of the RAD51 gene. EMBO Rep. 2006;7:219-24.
45. Powell SN, Kachnic LA. Roles of BRCA1 and BRCA2 in homologous recombination, DNA replication fidelity and the cellular response to ionizing radiation. Oncogene. 2003;22: 5784-91. (Pubitemid 37176700)
46. Bolderson E, Tomimatsu N, Richard DJ, Boucher D, Kumar R, Pandita TK, et al. Phosphorylation of Exo1 modulates homologous recombination repair of DNA double-strand breaks. Nucleic Acids Res. 2010;38:1821-31.
47. Johnson JI, Decker S, Zaharevitz D, Rubinstein LV, Venditti JM, Schepartz S, et al. Relationships between drug activity in NCI preclinical in vitro and in vivo models and early clinical trials. Br J Cancer. 2001;84:1424-31. (Pubitemid 32522115)
48. Vogelstein B, Fearon ER, Hamilton SR, Kern SE, Preisinger AC, Leppert M, et al. Genetic alterations during colorectal-tumor development. N Engl J Med. 1988;319:525-32.
49. Forrester K, Almoguera C, Han K, Grizzle WE, Perucho M. Detection of high incidence of K-ras oncogenes during human colon tumorigenesis. Nature. 1987;327:298-303. (Pubitemid 17075080)
50. Jansman FG, Sleijfer DT, de Graaf JC, Coenen JL, Brouwers JR. Management of chemotherapy-induced adverse effects in the treatment of colorectal cancer. Drug Saf. 2001;24:353-67. (Pubitemid 32417534)
51. Spiliotis JD. Peritoneal carcinomatosis cytoreductive surgery and HIPEC: a ray of hope for cure. Hepatogastroenterology. 2010;57:1173-7.
52. Rodel C, Sauer R. Integration of novel agents into combinedmodality treatment for rectal cancer patients. Strahlenther Onkol. 2007;183:227-35. (Pubitemid 46725993)